Timothy Sullivan
Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
December 19, 2017 10:16 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
December 08, 2017 16:34 ET | Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
November 13, 2017 16:05 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 08, 2017 21:38 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis logo.jpg
Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
December 02, 2016 08:00 ET | Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...
Apellis logo.jpg
Apellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific Meetings
November 21, 2016 08:00 ET | Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced today it will...